SOAT1 and acute lymphoblastic leukemia: Targeting JAK/STAT pathway with Ruxolitinib increased the sensitivity of human LOUCY ETP-ALL to SP2509 which resulted in increased apoptosis of human LOUCY ETP-ALL.